Skip to main content

Research Repository

Advanced Search

Cystic fibrosis microbiology: advances in antimicrobial therapy

Waters, Valerie; Smyth, Alan R.

Authors

Valerie Waters

Profile Image

ALAN SMYTH alan.smyth@nottingham.ac.uk
Professor of Child Health



Abstract

Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to advancements in antimicrobial treatments. New aerosolized antibiotic formulations have recently been introduced (such as inhaled aztreonam), and others are in development (inhaled levofloxacin and liposomal amikacin). Licensed dry powder formulations include tobramycin inhalation powder and dry powder colistimethate (available in Europe). Although inhaled antibiotics have the advantage of being able to deliver high intrapulmonary concentrations of drug, antimicrobial resistance can still develop and is a concern in CF. Antimicrobial resistance might be mitigated by using non-antibiotic treatments, antibiotic adjuvants, which have activity against bacteria. Examples include agents such as gallium, antimicrobial peptides and anti-biofilm compounds such as alginate oligosaccharides (OligoG) and garlic. Vaccination strategies and antibody therapy (IgY) against Pseudomonas aeruginosa have also been attempted to prevent initial infection with this organism in CF. Although aggressive and long-term use of antibiotics has been crucial in slowing lung function decline and improving survival in people with CF, it has added a significant burden of care and associated toxicities in these individuals. Careful surveillance and the use of preventative strategies for antibiotic related toxicity (such as nephrotoxicity and ototoxicity) are essential. Continued development of effective antimicrobial agents that can function in the conditions encountered in the CF lung, such as against bacterial biofilm growth and under anaerobic conditions, is needed.

Citation

Waters, V., & Smyth, A. R. (2015). Cystic fibrosis microbiology: advances in antimicrobial therapy. Journal of Cystic Fibrosis, 14(5), doi:10.1016/j.jcf.2015.02.005

Journal Article Type Article
Publication Date Sep 1, 2015
Deposit Date Feb 15, 2016
Publicly Available Date Feb 15, 2016
Journal Journal of Cystic Fibrosis
Print ISSN 1569-1993
Electronic ISSN 1873-5010
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 14
Issue 5
DOI https://doi.org/10.1016/j.jcf.2015.02.005
Public URL http://eprints.nottingham.ac.uk/id/eprint/31681
Publisher URL http://www.sciencedirect.com/science/article/pii/S1569199315000430
Copyright Statement Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0

Files


Waters Advances in antimicrobial therapy 02-03-2015.pdf (240 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0


Waters Table 1 02-05-2015.pdf (63 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by-nc-nd/4.0





You might also like



Downloadable Citations